The importance of being PI3K in the RAS signaling network
C Cuesta, C Arévalo-Alameda, E Castellano - Genes, 2021 - mdpi.com
Ras proteins are essential mediators of a multitude of cellular processes, and its
deregulation is frequently associated with cancer appearance, progression, and metastasis …
deregulation is frequently associated with cancer appearance, progression, and metastasis …
The PI3K/AKT/mTOR interactive pathway
T Ersahin, N Tuncbag, R Cetin-Atalay - Molecular BioSystems, 2015 - pubs.rsc.org
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR)
signalling pathway is hyperactivated or altered in many cancer types and regulates a broad …
signalling pathway is hyperactivated or altered in many cancer types and regulates a broad …
Realizing cancer precision medicine by integrating systems biology and nanomaterial engineering
Many clinical trials for cancer precision medicine have yielded unsatisfactory results due to
challenges such as drug resistance and low efficacy. Drug resistance is often caused by the …
challenges such as drug resistance and low efficacy. Drug resistance is often caused by the …
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Nearly all patients with BRAF-mutant melanoma will progress on BRAF inhibitor
monotherapy and combination BRAF/MEK inhibitor therapy within the first year of therapy. In …
monotherapy and combination BRAF/MEK inhibitor therapy within the first year of therapy. In …
[HTML][HTML] Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
Alterations of the EGFR/ERK and Hippo/YAP pathway have been found in non-small cell
lung cancer (NSCLC). Herein, we show that ERK1 and ERK2 have an effect on the …
lung cancer (NSCLC). Herein, we show that ERK1 and ERK2 have an effect on the …
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial
Purpose: The clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in
70% to 80% of patients with acute myelogenous leukemia (AML), is unknown. Experimental …
70% to 80% of patients with acute myelogenous leukemia (AML), is unknown. Experimental …
[HTML][HTML] Multiplexed fluorescence imaging of ERK and Akt activities and cell-cycle progression
The Ras-ERK pathway controls cell proliferation and differentiation, whereas the PI3K-Akt
pathway plays a role in the process of cell-cycle progression and cell survival. Both …
pathway plays a role in the process of cell-cycle progression and cell survival. Both …
Activation of spinal chemokine receptor CXCR3 mediates bone cancer pain through an Akt-ERK crosstalk pathway in rats
XH Guan, QC Fu, D Shi, HL Bu, ZP Song… - Experimental …, 2015 - Elsevier
Previously, we showed that activation of the spinal CXCL9, 10/CXCR3 pathway mediated
bone cancer pain (BCP) in rats. However, the cellular mechanism involved is poorly …
bone cancer pain (BCP) in rats. However, the cellular mechanism involved is poorly …
The inflammatory kinase IKKα phosphorylates and stabilizes c-Myc and enhances its activity
Abstract Background The IκB kinase (IKK) complex, comprising the two enzymes IKKα and
IKKβ, is the main activator of the inflammatory transcription factor NF-κB, which is …
IKKβ, is the main activator of the inflammatory transcription factor NF-κB, which is …
The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2
C Choi, DM Helfman - Oncogene, 2014 - nature.com
Abstract MDA-MB-231 LM2 (herein referred to as LM2) is a derivative of MDA-MB-231 cells
that was selected for its ability to metastasize to lung tissue in vivo. We investigated cellular …
that was selected for its ability to metastasize to lung tissue in vivo. We investigated cellular …